Boston Scientific Corporation

Boston Scientific Corporation

BSX

$44.32

Updated: 03/11/2026, 14:42:22

Market Cap
$64.23B
Sector
Healthcare
Industry
Medical - Devices
Country
US

No historical data available

Company Profile

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

USD
NYSE
CEO: Michael F. Mahoney
Employees: 59,000
https://www.bostonscientific.com
Asset Summaries
Latest generated summaries for BSX

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
BSX-10-k-fy2025.html3.0 MBtext/htmlENFiled 17/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 60 KPI observations

Revenue

$20.1B

FY 2025 · Reported

Net income

$2.9B

FY 2025 · Reported

Gross margin

69.0%

FY 2025 · Calculated

Free cash flow

$3.7B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

N/A

FY — · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Electrophysiology — FARAPULSE PFA system
WATCHMAN LAAC devices
MedSurg product families
Cardiovascular product families beyond EP/Watchman

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Global medical device company advancing less-invasive medicine for 45+ years

99%
Source evidence
“Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.”

Two reportable segments: MedSurg and Cardiovascular

MedSurg and Cardiovascular segments

99%
Source evidence
“Our core businesses are organized into two reportable segments: MedSurg and Cardiovascular. In the fourth quarter of 2025, an organizational change combined our legacy Cardiology and Peripheral Interventions businesses into a single Cardiovascular business.”

Customer base: hospitals, physicians, providers

Products purchased principally by hospitals, physicians and other health care providers who bill third-party payers including Medicare and Medicaid in the U.S. and private health plans

90%
Source evidence
“Our products are purchased principally by hospitals, physicians and other health care providers around the world that typically bill various third-party payers, including government programs, authorities or agencies (e.g., Medicare and Medicaid in the U.S.) and private health plans”

Electrophysiology — FARAPULSE PFA system

FARAPULSE PFA launched 2024; rapid conversion to PFA; now predominant component of EP revenue

98%
Source evidence
“Since the launch of the FARAPULSE™ PFA System in 2024, we have observed rapid conversion from legacy treatment modalities to PFA. It is now the predominant component of our Electrophysiology business unit and revenue.”

WATCHMAN LAAC devices

WATCHMAN is the leading device in percutaneous LAAC globally

97%
Source evidence
“WATCHMAN™ is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is the leading device in percutaneous LAAC globally.”

MedSurg product families

Endoscopy, Urology and Neuromodulation device portfolios

95%
Source evidence
“Our Endoscopy business unit develops and manufactures minimally invasive devices for diagnosing and treating gastrointestinal and pancreaticobiliary conditions and for supporting weight loss in patients with obesity.”

Cardiovascular product families beyond EP/Watchman

ICVT, CRM and Interventional Oncology portfolios

94%
Source evidence
“Our Interventional Cardiology and Vascular Therapies business unit develops and manufactures technologies to diagnose and treat complex coronary, peripheral and venous diseases”

Positioning and strategy

Pending acquisition of Penumbra (~$14.5 billion)

Definitive agreement dated January 15, 2026 to acquire Penumbra for approximately $14.500 billion, expected to close in 2026; ~$11.000 billion funded with cash and new debt, remainder in BSX common stock

99%
Source evidence
“The definitive agreement, entered into on January 15, 2026, to acquire Penumbra, for approximately $14.500 billion, which is expected to close during 2026, subject to customary closing conditions.”

Pending acquisition of Penumbra ($14.5B)

Definitive agreement to acquire Penumbra for ~$14.5B ($374/share), expected to close 2026

98%
Source evidence
“The purchase price is valued at $374 per share, or approximately $14.500 billion. The transaction is expected to close during 2026, subject to customary closing conditions.”

Acquisition of remaining stake of Nalu Medical

January 27, 2026 acquisition of the remaining stake of Nalu Medical for an upfront cash payment of approximately $517 million, net of cash acquired

97%
Source evidence
“The January 27, 2026 acquisition of the remaining stake of Nalu Medical, consisting of an upfront cash payment of approximately $517 million, net of cash acquired”

2025 tuck-in acquisitions: Bolt Medical and SoniVie

Completed acquisitions of Bolt Medical and SoniVie in Q2 2025

96%
Source evidence
“In the second quarter of 2025, we completed our acquisition of the remaining shares of Bolt Medical, Inc. ... In addition, we completed the acquisition of the remaining shares of SoniVie Ltd.”

Competitor landscape

Primary competitors include large multi-line manufacturers and niche medical device firms; also competition from pharma, biotech and diagnostics companies offering alternative therapies; consolidation among competitors may give them greater resources

90%
Source evidence
“Our primary competitors include large manufacturers with multiple lines of business and competing products... We also face competition from non-medical device companies, including pharmaceutical companies, biotech companies and providers of various diagnostic solutions”

Growth drivers named for 2025

Farapulse, Watchman, AGENT DCB led 2025 growth

96%
Source evidence
“reported net sales growth was primarily driven by the growth of our Electrophysiology business unit, led by our Farapulse™ Pulsed Field Ablation (PFA) System, continued market penetration of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN™ LAAC Devices, as well as our coronary therapies franchise led by our AGENT™ Drug-Coated Balloon.”

Procedure volumes and market size key demand drivers

Declines in market sizes, market share, average selling prices or procedural volumes could materially adversely affect results

85%
Source evidence
“Decreases in market sizes or our market share and declines in average selling prices or procedural volumes could materially adversely affect our results of operations or financial condition.”

Five strategic imperatives

Five strategic imperatives including category leadership, high-growth adjacencies, global expansion

95%
Source evidence
“We aim to: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth and Develop Key Capabilities.”

Risks, financing, and outlook

Discontinuation of ACURATE aortic valve systems

Discontinued ACURATE TAVR systems worldwide; refocusing resources on remainder of portfolio

95%
Source evidence
“we announced the discontinuation of worldwide sales of the ACURATE Neo2™ and ACURATE Prime™ Aortic Valve Systems and that we would no longer pursue U.S. FDA approval for ACURATE”

Tariff cost exposure and macro uncertainty

Anticipates incremental tariff costs on U.S. imports and potential China tariffs; supply chain and wage inflation pressures

93%
Source evidence
“We continue to anticipate incurring incremental costs under the current schedule of tariffs on U.S. imports announced by the U.S. government, as well as any potential increases in tariffs introduced by China on U.S. manufactured products.”

No shares repurchased under $1.000 billion program

No repurchases in 2025 or 2024; full $1.000 billion authorization available as of December 31, 2025; ~263 million treasury shares

95%
Source evidence
“We did not repurchase any shares of our common stock in 2025 or 2024, and had the full amount available under the authorization as of December 31, 2025.”

Medical device regulation — FDA and EU MDR

FDA regulation under FDC Act; EU MDR compliance required; transitional period extended to 2027 (high-risk) and 2028 (lower-risk); non-US approvals renewed every four to five years

94%
Source evidence
“In 2023, the European Commission extended the transitional period to 2027 for certain high risk class devices and 2028 for lower risk class medical devices.”

Global privacy and data-protection regulation (GDPR, PIPL)

Subject to GDPR, China PIPL (with data-localization and government-approval requirements), and US health-data regulations; non-compliance could result in fines and business disruptions

93%
Source evidence
“China’s data‑protection and cross‑border transfer laws, including requirements under the Personal Information Protection Law (PIPL) and related regulations, impose strict obligations on how data involving Chinese individuals may be handled”

Cybersecurity and AI-related risks

Cyber-attacks, including via generative AI and quantum computing, ransom demands, and legacy third-party software vulnerabilities could disrupt operations or harm patients

93%
Source evidence
“This includes emerging technologies which increase our threat landscape, such as generative AI and quantum computing, which are evolving rapidly in their practicality and use for cyber-attacks”

Health care policy and reimbursement changes

Government and private initiatives to limit health care cost growth and reform payment structures could lower reimbursements or reduce procedure volumes, adversely affecting results

92%
Source evidence
“any changes that lower reimbursements for either our products and/or procedures using our products reduce medical procedure volumes and/or increase cost containment pressures”

Talent attraction and retention risk

Substantial competition for key personnel; loss of key employees or skilled labor shortage could increase labor costs and adversely affect the business

90%
Source evidence
“A shortage of skilled labor could also require higher wages that would increase labor costs.”

Pricing pressure from healthcare consolidation and tenders

Consolidation of purchasing power and country tenders (some favoring local players) drive pricing pressure, lower average selling prices, and possible exclusion from market segments

90%
Source evidence
“a growing number of countries have instituted or are contemplating introducing regional or national tender processes driven primarily by price. In some cases, these or other local procurement processes may favor local players to multinational companies like us.”

Reimbursement dependence

Limited demand for new products unless reimbursement approval is obtained; payers require health economic evidence and real-world outcomes data, potentially funded by company via post-market studies/registries

90%
Source evidence
“We may find limited demand for otherwise promising new products unless reimbursement approval is obtained from private and governmental third-party payers.”

Natural disasters and climate change risks

Climate change and extreme weather could disrupt supply chain, manufacturing, distribution, raw materials, energy supply, and transportation; increased environmental regulation may raise compliance costs

90%
Source evidence
“Natural disasters, extreme weather and other conditions caused by or related to climate change could adversely impact our supply chain, including manufacturing and distribution networks”

Macroeconomic conditions risk

Challenging global macro conditions including inflation, interest rates, monetary policy, exchange rates, tariff and trade policies and geopolitical developments could adversely impact business; recession could reduce customer spending

85%
Source evidence
“The global macroeconomic environment has continued to experience challenging conditions and uncertainty, including with respect to inflation, interest rates, monetary policy, exchange rates, tariff and trade policies and geopolitical developments”

Site-of-care shift risk

Shifts in sites of care and associated changes in coverage, reimbursement, payment terms and provider economics may impact procedure volumes, product mix, and pricing and contracting

85%
Source evidence
“Shifts in sites of care including migration of procedures from inpatient to outpatient, ambulatory surgical centers or office-based settings, and associated changes in coverage, reimbursement, payment terms and provider economics, may impact procedure volumes, product mix, and pricing and contracting.”

Product obsolescence / launch timing risk

Need to devote continued efforts and financial resources to develop or acquire scientifically advanced technologies; delay in next-generation launches may cause market share declines and physician confidence loss

85%
Source evidence
“a delay in the timing of the launch of next-generation products and the overall performance of, and continued physician confidence in, those products may result in declines in our market share”

Credit market access risk for M&A financing

Heightened interest rate environment has caused and may continue to cause disruption in financial markets, affecting ability to access credit markets including for M&A financing

85%
Source evidence
“These conditions could affect our ability to access credit markets, including to obtain financing for mergers and acquisitions (M&A) or for other general purposes.”

Supply chain and cost inflation risk

Economic conditions could adversely affect third-party vendors in supply chain/manufacturing, reducing supply or raising prices of materials and components; inflationary pressure may increase wage and materials costs

85%
Source evidence
“Continued inflationary pressure may also increase certain operational costs, including due to wage increases, or increases in the cost of materials or components.”

Accounts receivable factoring programs

Company operates accounts receivable factoring programs in certain European and Asian countries; global slowdown or sovereign debt issues may impact this ability

80%
Source evidence
“we have accounts receivable factoring programs in certain European and Asian countries. A slowdown in the global economy or sovereign debt issues may impact our ability”

Emerging competitor models and automation technologies

New competitors may emerge, potentially including companies introducing new sales or distribution models or leveraging genomic, robotic, navigation, and/or other automation technologies

80%
Source evidence
“New competitors may emerge in the future, potentially including companies introducing new sales or distribution models to our industry or leveraging genomic, robotic, navigation, and/or other automation technologies.”

Material exposure graph

FARAPULSE PFA System
Revenue Exposure

FARAPULSE launched in the U.S. in early 2024 and is now the predominant component of Electrophysiology revenue, driving consolidated sales growth of 19.9% in 2025.

Relevance 95·Dependency 85·Confidence 96
Source evidence
“led by the continued growth of our Farapulse™ Pulsed Field Ablation System which launched in the U.S. in early 2024”
Third-party payer reimbursement (Medicare/Medicaid, private plans, tenders)
Regulatory Exposure

Reimbursement approval is critical to product acceptance; changes in U.S., Japan, China reimbursement systems could materially adversely affect results.

Relevance 90·Dependency 85·Confidence 90
Source evidence
“legislative or administrative reforms to the reimbursement systems in the U.S., Japan, China, or other countries in a manner that significantly reduce or eliminate reimbursement for procedures using our medical devices”
Hospitals, physicians and health care providers
Customer Exposure

Products purchased principally by hospitals, physicians and other providers who bill third-party payers; consolidation of purchasing power and payer policies affect demand and pricing.

Relevance 90·Dependency 85·Confidence 90
Source evidence
“Our products are purchased principally by hospitals, physicians and other health care providers around the world”
Federal Food, Drug and Cosmetic Act (FDA)
Regulatory Exposure

US commercialization of products requires FDA clearance or approval under the FDC Act, which can be lengthy, costly and may limit indicated uses.

Relevance 88·Dependency 82·Confidence 94
Source evidence
“medical devices must receive FDA clearance or approval or an exemption from such clearance or approval before they can be commercially marketed in the U.S.”
EU Medical Device Regulation (MDR)
Regulatory Exposure

Boston Scientific's EU market access depends on MDR compliance and CE Marking, with extended transition periods to 2027/2028 for certain devices.

Relevance 85·Dependency 80·Confidence 94
Source evidence
“In the EU, we are required to comply with the Medical Device Regulation (MDR), which became effective in May 2021 and changed multiple aspects of the regulatory framework for CE Marking”
WATCHMAN LAAC Devices
Revenue Exposure

Continued market penetration of WATCHMAN LAAC procedures was a primary driver of 2025 Cardiovascular sales growth.

Relevance 80·Dependency 65·Confidence 90
Source evidence
“continued market penetration of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN™ LAAC Devices”
tariffs
Cost Driver

Company anticipates incremental costs under the current schedule of U.S. tariffs on imports and potential China tariff increases on U.S.-made products.

Relevance 80·Dependency 60·Confidence 90
Source evidence
“We continue to anticipate incurring incremental costs under the current schedule of tariffs on U.S. imports announced by the U.S. government, as well as any potential increases in tariffs introduced by China on U.S. manufactured products.”
Third-party vendors / supply chain
Supplier Dependency

Economic conditions could reduce or interrupt supply of materials and components used in manufacturing products.

Relevance 75·Dependency 70·Confidence 85
Source evidence
“these conditions could also adversely affect our third-party vendors, including those that we utilize in our supply-chain and manufacturing operations, which may lead to a reduction or interruption in the supply of materials and components”
Inflation and macroeconomic conditions
Cost Driver

Inflation, interest rates, exchange rates, tariffs and geopolitical developments affect operational costs, customer spending and supplier/distributor health.

Relevance 75·Dependency 60·Confidence 85
Source evidence
“Continued inflationary pressure may also increase certain operational costs, including due to wage increases, or increases in the cost of materials or components.”
Health care cost containment and reimbursement policy
Demand Driver

Changes that lower reimbursements, reduce procedure volumes, or increase cost containment pressures could adversely affect demand and results.

Relevance 75·Dependency 60·Confidence 92
Source evidence
“any changes that lower reimbursements for either our products and/or procedures using our products reduce medical procedure volumes”
FDA and PMDA approvals
Regulatory Exposure

Revenue expansion depends on regulatory approvals; FDA (Q2 2025) and Japan PMDA (Q3 2025) label expansions for FARAPULSE, and FDA clearance distinctions like Intracept, drive product adoption; discontinuation decision on ACURATE followed regulatory pathway considerations.

Relevance 70·Dependency 60·Confidence 88
Source evidence
“We received FDA approval in the United States, and Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan, in the second and third quarters of 2025, respectively, to expand instructions for use labeling to include the treatment of drug refractory, symptomatic persistent AF with the FARAPULSE™ PFA System.”
EU General Data Protection Regulation (GDPR)
Regulatory Exposure

GDPR imposes strict data-protection requirements and significant potential penalties affecting operations and data transfers.

Relevance 70·Dependency 60·Confidence 92
Source evidence
“In the European Union, the General Data Protection Regulation (GDPR) imposes strict requirements and significant potential penalties.”
China
Revenue Exposure

Emerging Markets growth ($2,985M in 2025) was primarily driven by China; China tariffs on U.S.-manufactured products are also cited as a risk.

Relevance 70·Dependency 55·Confidence 88
Source evidence
“Reported net sales growth was primarily driven by growth in China, fueled by the breadth of our portfolio and focus on innovation and strong commercial execution.”
AI and digital technologies
Competitive Exposure

AI/ML are increasingly important to competitive environment and R&D; company believes new digital capabilities are needed to remain competitive.

Relevance 70·Dependency 55·Confidence 85
Source evidence
“We believe we will need to develop new and enhanced digital capabilities and competences in order to remain competitive.”
Economic slowdown / recession
Demand Driver

A general economic slowdown or recession may decrease customer spending and demand for products and impair customers' ability to pay.

Relevance 65·Dependency 55·Confidence 85
Source evidence
“If there were a general economic slowdown or recession, we may experience decreased customer spending or demand for our products and services”
Changing trade and tariff policies
Geopolitical Exposure

Forward-looking risk factors explicitly cite changing trade and tariff policies among conditions that could cause results to vary materially.

Relevance 65·Dependency 55·Confidence 80
Source evidence
“future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events and tensions”
Cybersecurity threat landscape (generative AI, quantum computing)
Customer Exposure

Evolving cyber-attacks using generative AI and quantum computing could disrupt operations, expose patient data, or harm patients.

Relevance 65·Dependency 50·Confidence 90
Source evidence
“generative AI and quantum computing, which are evolving rapidly in their practicality and use for cyber-attacks”
inflation
Cost Driver

Continued increases in cost and limited availability of raw materials, components and inputs, plus wage and distribution cost increases amid global supply chain inflation.

Relevance 65·Dependency 50·Confidence 85
Source evidence
“we have continued to experience, and may in the future experience, increases in cost and limited availability of certain raw materials, components, and other inputs necessary to manufacture and distribute our products due to constraints and inflation within the global supply chain”
AGENT Drug-Coated Balloon
Revenue Exposure

Coronary therapies franchise led by AGENT Drug-Coated Balloon cited as a primary growth driver in 2025.

Relevance 65·Dependency 45·Confidence 85
Source evidence
“as well as our coronary therapies franchise led by our AGENT™ Drug-Coated Balloon”
Interest rates and credit market conditions
Revenue Exposure

Rate environment disrupts financial markets, affecting credit market access for M&A, supplier financing, and customer purchases especially of capital equipment.

Relevance 60·Dependency 50·Confidence 80
Source evidence
“These conditions could affect our ability to access credit markets, including to obtain financing for mergers and acquisitions (M&A) or for other general purposes.”
Climate change and extreme weather
Cost Driver

Climate change and natural disasters could disrupt supply chain, manufacturing, raw materials, and energy supply, and increase compliance costs.

Relevance 60·Dependency 45·Confidence 90
Source evidence
“could adversely impact our supply chain, including manufacturing and distribution networks, the availability and cost of raw materials and components, energy supply, transportation”
Skilled labor shortage
Cost Driver

A shortage of skilled labor could require higher wages and increase labor costs; competition for key personnel is substantial.

Relevance 55·Dependency 45·Confidence 90
Source evidence
“A shortage of skilled labor could also require higher wages that would increase labor costs.”
China Personal Information Protection Law (PIPL)
Regulatory Exposure

PIPL and related Chinese regulations impose data-localization and government-approval requirements affecting data handling in China.

Relevance 55·Dependency 40·Confidence 90
Source evidence
“China’s data‑protection and cross‑border transfer laws, including requirements under the Personal Information Protection Law (PIPL)”
foreign currency fluctuations
Revenue Exposure

FX fluctuations reduced 2025 reported growth by 0.7 percentage points; operational (constant currency) growth was 19.2% vs 19.9% reported.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“Impact of foreign currency fluctuations(0.7)%0.9 % Net sales operational growth (non-GAAP measure) 19.2 %18.5 %”
Full company information
Latest profile, trading, valuation, and identifier data stored for BSX.
Share price
$44.32
Market cap
$64.23B
Exchange
NYSE
Currency
USD
CEO
Michael F. Mahoney
Employees
59,000
IPO date
19/05/1992
Beta
0.575
Last dividend
$0.00
Day range
$41.90 – $44.36
52-week range
$39.57 – $105.65
1-day performance
5.57%
1-year performance
12.00%
Current drawdown (1Y)
-58.05%
CIK
0000885725
CUSIP
101137107
ISIN
US1011371077
Created
07/12/2025, 03:07:36
Last update
03/11/2026, 14:42:22

Track Boston Scientific Corporation with an AI analyst

See which prediction-market events move BSX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to BSX from your Railway `news_articles` table.

Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months

The Motley Fool • STOCK • 13/06/2026, 02:15:00

Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Seeking Alpha • STOCK • 12/06/2026, 13:49:51

Boston Scientific (BSX) Rises Higher Than Market: Key Facts

Zacks Investment Research • STOCK • 04/06/2026, 21:01:13

Analyst Outlook Shifts for Boston Scientific (NYSE:BSX) Amid Watchman Product Concerns

Market Data • Market Data • 04/06/2026, 16:08:00

Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet

Zacks Investment Research • STOCK • 04/06/2026, 12:31:14

Why These Three Big Buybacks Are Sending Very Different Signals to Investors

MarketBeat • STOCK • 01/06/2026, 16:20:33

Boston Scientific Corporation (BSX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Seeking Alpha • STOCK • 29/05/2026, 23:24:04

BSX vs. ABT: Which Medical Stock Has More Upside Potential?

Zacks Investment Research • STOCK • 29/05/2026, 12:16:18

Why Boston Scientific Stock Was Sliding This Week

Fool - Investing News • STOCK • 29/05/2026, 06:47:58

Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts

Zacks Investment Research • STOCK • 28/05/2026, 21:01:11

Boston Scientific (BSX): Bullish Analyst Sets $75 Target

Market Data • Market Data • 27/05/2026, 18:18:56

Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth

Zacks Investment Research • STOCK • 26/05/2026, 12:56:30